AG真人官方

Form 4 Overview 鈥� Inozyme Pharma, Inc. (INZY)

This Form 4 discloses that Sanjay Subramanian, the company鈥檚 Senior Vice President, Chief Financial Officer and Head of Business Development, no longer holds any equity interests in Inozyme Pharma following the closing of a cash-only merger with BioMarin Pharmaceutical Inc. on 1 July 2025.

• Merger mechanics: BioMarin鈥檚 wholly-owned Incline Merger Sub completed a tender offer and subsequent merger, paying $4.00 in cash per Inozyme common share (the 鈥淢erger Consideration鈥�).
• Common shares: 39,701 shares held by the reporting person were tendered for the $4.00 cash consideration.
• Restricted Stock Units (RSUs): 38,500 RSUs automatically accelerated, vested and were cancelled for a cash payment of $4.00 per underlying share.
• Stock options: A total of 460,000 options with strike prices of $3.96, $3.30 and $1.06 were fully vested and converted into the right to receive the intrinsic value (cash equal to $4.00 minus the option鈥檚 exercise price) per underlying share.
• Post-merger ownership: After these transactions, the reporting person reports zero derivative or non-derivative securities, reflecting the company鈥檚 transition to a wholly-owned BioMarin subsidiary.

The filing formally documents insider disposition of securities pursuant to the merger agreement and confirms that Inozyme鈥檚 public equity has effectively been cashed out at the specified price.

Form 4 highlights: Inozyme Pharma, Inc. (INZY) Chief Operating Officer Matthew Winton filed a Form 4 on 3 July 2025 reporting the cash disposal of all of his equity holdings in connection with the company鈥檚 merger with BioMarin Pharmaceutical Inc.

• Merger mechanics: BioMarin, through Incline Merger Sub, completed a cash tender offer and subsequent merger on 1 July 2025, paying $4.00 per INZY share. Inozyme is now a wholly-owned subsidiary of BioMarin.
• Common shares: 21,743 shares owned directly by the reporting person were tendered for the $4.00 cash consideration.
• Restricted Stock Units: 41,500 RSUs automatically accelerated, vested and were cancelled for a cash payment of $4.00 per underlying share.
• Stock options: 145,000 options with a $1.06 exercise price vested and were cashed out for the intrinsic value ( $4.00 鈥� $1.06 ) per share.
• Following these transactions, the insider reports zero remaining beneficial ownership of INZY securities.

The filing confirms that the equity portion of the merger consideration has been delivered and that insider equity has been fully settled in cash, signalling the practical completion of the acquisition.

Form 4 Overview: The filing details the final disposition of Inozyme Pharma, Inc. (INZY) equity held by director Axel Bolte in connection with the closing of BioMarin Pharmaceutical鈥檚 all-cash acquisition of the company on 1 July 2025.

• Common stock: 423,926 shares tendered and converted into cash at $4.00 per share, the agreed Merger Consideration.
• Stock options: 鈥� 234,176 options (exercise $2.02, exp. 6/19/2029) and 鈥� 159,187 options (exercise $2.77, exp. 4/22/2030) were automatically accelerated, cancelled and cashed out for the intrinsic value (Merger Consideration minus exercise price) per option share.
• After the transactions, the reporting person holds zero INZY securities; Inozyme is now a wholly-owned subsidiary of BioMarin and will cease public trading.

Investor takeaway: The Form 4 confirms that the merger has reached the final settlement stage, signalling the end of INZY as a standalone public equity and locking in the previously announced $4.00 cash payment for all former shareholders.

Form 4 highlights: Director Lynne Marie Sullivan reports the disposition of employee stock options in connection with the closing of Inozyme Pharma, Inc.鈥檚 merger with BioMarin Pharmaceutical Inc. on 1 July 2025. The filing confirms that Incline Merger Sub, a wholly-owned subsidiary of BioMarin, merged with and into Inozyme after completing a cash tender offer for all outstanding common shares at $4.00 per share.

Key transaction details

• Derivative security: Stock option (right to buy) covering 28,368 INZY common shares.
• Exercise price: $2.77 per share.
• Form 4 code: 鈥淒鈥� (disposition) 鈥� the option was cancelled and converted to cash.
• Cash received: For each share underlying the option, the holder receives the difference between the $4.00 merger consideration and the $2.77 exercise price, subject to withholding.
• Post-transaction holdings: 0 derivative securities remain; reporting person has no disclosed direct or indirect ownership of options after the merger.

Merger mechanics: Under the Merger Agreement dated 16 May 2025, all company options with exercise prices below $4.00 automatically vested, were cancelled at closing and exchanged for cash. Inozyme now operates as a wholly-owned subsidiary of BioMarin.

Investor takeaway: The filing is administrative, documenting option cash-out terms already embedded in the merger. Public shareholders will likewise receive $4.00 per share in cash; INZY stock will cease to trade independently.

Inozyme Pharma, Inc. (INZY) 鈥� Insider Form 4 Overview

CEO & Chairman Douglas A. Treco filed a Form 4 detailing the automatic disposition of his entire equity stake following the closing of Inozyme鈥檚 merger with BioMarin Pharmaceutical Inc. on 1 July 2025. Under the Agreement and Plan of Merger dated 16 May 2025, BioMarin鈥檚 wholly owned Incline Merger Sub acquired all outstanding Inozyme shares for $4.00 cash per share.

• Common stock: 43,861 shares were tendered at $4.00, eliminating Treco鈥檚 direct share ownership.
• Restricted stock units: 150,000 RSUs automatically accelerated, vested, and converted to a $4.00 cash payout per underlying share.
• Stock options: 86,979 options (exercise $2.77) and 400,000 options (exercise $1.06) vested and were cancelled in exchange for the cash spread between the $4.00 consideration and each strike price.

Following the transactions, Treco reports zero remaining beneficial ownership, reflecting Inozyme鈥檚 status as a wholly owned BioMarin subsidiary. The filing is largely procedural, confirming final insider settlement terms aligned with the previously announced merger.

Form 4 Overview 鈥� Inozyme Pharma, Inc. (INZY)

This Form 4 discloses that Robert L. Hopfner, a director of Inozyme Pharma and managing partner of Pivotal bioVenture Partners, disposed of his indirect holdings in the company on 1 July 2025 as a result of Inozyme鈥檚 acquisition by BioMarin Pharmaceutical Inc.

• Transaction structure: The shares were tendered pursuant to the Agreement and Plan of Merger dated 16 May 2025 between Inozyme, BioMarin and Incline Merger Sub.
• Consideration: All common shares were exchanged for $4.00 cash per share (the 鈥淢erger Consideration鈥�), without interest and subject to tax withholding.
• Holdings affected:
  • Pivotal bioVenture Partners Fund I, L.P. 鈥� 2,923,110 shares
  • Pivotal bioVenture Partners Fund II, L.P. 鈥� 1,571,741 shares
  Total indirect disposition: 4,494,851 shares.
• Post-merger status: Effective 1 July 2025, Incline Merger Sub merged with and into Inozyme, making Inozyme a wholly-owned subsidiary of BioMarin.

No derivative securities were reported. The filing is made by one reporting person and executed by power of attorney.

Inozyme Pharma, Inc. (INZY) has submitted a Form 25 to the SEC, signaling the removal of its common stock from listing and registration on the Nasdaq Stock Market under Section 12(b) of the Exchange Act.

The document, signed by Nasdaq AVP Tara Petta on 2025-07-01, states that the exchange has met all procedural requirements of Rule 12d2-2 for striking the security. The filing covers only the company鈥檚 common stock and does not disclose the reason for the delisting鈥攚hether involuntary (e.g., non-compliance) or voluntary (e.g., merger, alternate listing).

After effectiveness, trading in INZY shares on Nasdaq will cease and the Section 12(b) registration will be withdrawn 10 days later, materially affecting share liquidity, index eligibility, and disclosure obligations. Investors should watch subsequent SEC filings or company announcements for context on trading venue migration (such as OTC) and any strategic ramifications.